Susquehanna International Group, LLP Tg Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 602,388 shares of TGTX stock, worth $18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

602,388

Previous 1,087,069 44.59%

Holding current value

$18 Million

Previous $19.3 Million 27.14%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$17.21 - $25.28 $8.34 Million - $12.3 Million	-484,681 Reduced 44.59%	602,388 $14.1 Million
Q2 2024 Aug 15, 2024	BUY	$13.32 - $19.19 $62,723 - $90,365	4,709 Added 0.44%	1,087,069 $19.3 Million
Q1 2024 May 07, 2024	SELL	$13.02 - $21.3 $11.3 Million - $18.5 Million	-866,297 Reduced 44.46%	1,082,360 $16.5 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $3.81 Million - $10.7 Million	570,896 Added 41.44%	1,948,657 $33.3 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $4.18 Million - $13.2 Million	499,976 Added 56.96%	1,377,761 $11.5 Million
Q2 2023 Aug 11, 2023	SELL	$15.48 - $35.0 $6.2 Million - $14 Million	-400,463 Reduced 31.33%	877,785 $21.8 Million
Q1 2023 May 16, 2023	BUY	$10.23 - $19.34 $940,955 - $1.78 Million	91,980 Added 7.75%	1,278,248 $19.2 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $768,012 - $1.81 Million	153,296 Added 14.84%	1,186,268 $14 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $926,736 - $1.7 Million	202,787 Added 24.43%	1,032,972 $6.12 Million
Q2 2022 Aug 15, 2022	SELL	$3.74 - $10.66 $576,872 - $1.64 Million	-154,244 Reduced 15.67%	830,185 $3.53 Million
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $1.27 Million - $3.32 Million	-162,422 Reduced 14.16%	984,429 $9.36 Million
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $7.48 Million - $17.5 Million	-491,930 Reduced 30.02%	1,146,851 $21.8 Million
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $4.43 Million - $8.23 Million	203,505 Added 14.18%	1,638,781 $54.5 Million
Q2 2021 Aug 11, 2021	BUY	$32.5 - $48.96 $15.9 Million - $23.9 Million	488,642 Added 51.62%	1,435,276 $55.7 Million
Q1 2021 May 17, 2021	BUY	$41.61 - $54.3 $15.8 Million - $20.6 Million	379,308 Added 66.86%	946,634 $45.6 Million
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $2.21 Million - $4.8 Million	87,394 Added 18.21%	567,326 $29.5 Million
Q3 2020 Nov 16, 2020	BUY	$18.49 - $27.24 $5.02 Million - $7.39 Million	271,474 Added 130.23%	479,932 $12.8 Million
Q2 2020 Aug 14, 2020	SELL	$8.9 - $21.84 $1.11 Million - $2.73 Million	-124,936 Reduced 37.47%	208,458 $4.06 Million
Q1 2020 May 15, 2020	BUY	$7.14 - $15.99 $534,421 - $1.2 Million	74,849 Added 28.95%	333,394 $3.28 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $752,559 - $1.26 Million	139,881 Added 117.88%	258,545 $1.45 Million
Q2 2019 Aug 16, 2019	BUY	$6.27 - $8.65 $538,185 - $742,472	85,835 Added 261.46%	118,664 $1.03 Million
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $3.09 Million - $4.26 Million	-492,374 Reduced 93.75%	32,829 $284,000
Q1 2019 May 15, 2019	BUY	$4.02 - $8.04 $2.05 Million - $4.09 Million	508,731 Added 3088.46%	525,203 $4.22 Million
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $1.03 Million - $1.72 Million	-299,222 Reduced 94.78%	16,472 $68,000
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $111,712 - $134,055	-8,937 Reduced 2.75%	315,694 $4.15 Million
Q1 2018 May 15, 2018	SELL	$8.7 - $16.8 $531,787 - $1.03 Million	-61,125 Reduced 15.85%	324,631 $4.61 Million
Q4 2017 Feb 14, 2018	BUY	$7.35 - $12.3 $1.45 Million - $2.43 Million	197,878 Added 105.32%	385,756 $3.16 Million
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $1.88 Million - $2.39 Million	187,878	187,878 $2.23 Million

Others Institutions Holding TGTX

# of Institutions

336

Shares Held

87.6M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.34B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Tg Therapeutics, Inc. Transaction History